Compounded Glutathione Recalled After Emergency Room Visits

A Texas compounding pharmacy's nationwide recall of an injectable wellness drug is drawing attention less for its own facts than for the company it keeps. On 1 October 2026, Greenwich Rx recalled ten lots of compounded Glutathione Injection after testing found potentially elevated endotoxin levels — the fourth Texas 503A compounder to pull the same drug for a quality failure since August.

What was recalled

The recalled product is compounded Glutathione Injection, 200 mg/mL, packaged in 10 mL multidose vials and labelled for subcutaneous injection only. Glutathione injections are widely sold through med-spa and wellness channels, marketed for uses such as skin brightening and antioxidant support, and are typically dispensed directly to patients rather than through a hospital pharmacy. Ten specific lots are affected, distributed nationwide between 26 June and 21 September 2026, with beyond-use dates spanning 2 October through 12 November 2026 — meaning some recalled product may still have been within its labelled shelf life when the recall was announced. Consumers who have the product are instructed to stop use immediately and contact the recall management firm, Sedgwick, for return instructions.

Why endotoxin contamination is a serious finding

Endotoxin is a component of the outer membrane of certain bacteria that remains biologically active even after the organism itself is no longer viable — meaning a product can test positive for endotoxin without any live bacteria being recoverable from it, and a sterility test alone would not catch it. Injected into the body, endotoxin can trigger a systemic inflammatory response: fever, chills, and in more severe cases a drop in blood pressure consistent with septic shock. For a compounder, an elevated endotoxin result typically points to a gap somewhere upstream of the final sterility test — in raw material quality, water system control, or environmental monitoring during fill — rather than a one-off packaging defect.

The off-label administration question

Greenwich Rx's recall notice connects two emergency department visits to the recall, both involving patients who received the product intravenously rather than subcutaneously, as labelled. The company has pointed to that route of administration, not the endotoxin finding itself, as the proximate cause of those specific adverse events. The two issues are related but distinct: an endotoxin-contaminated product is unsafe regardless of route, but IV administration delivers it directly into the bloodstream, removing the barrier that subcutaneous tissue would otherwise provide and making a systemic reaction more likely and more severe. For a product this widely used off-label in wellness settings, that distinction matters operationally — it is a second, independent risk layered on top of the contamination finding, not a restatement of it.

A fourth recall in a pattern, not an isolated event

Greenwich Rx is not the first Texas compounder to pull injectable glutathione this year. Victory Medical Center Pharmacy in Austin and Centric Compounding in Houston have both issued their own nationwide recalls of compounded glutathione products since August 2026, and Optimal Balance Pharmacy in Houston has as well — four 503A compounders, the same general product category, and the same broad contamination concern, within roughly two months of each other. None of the public notices to date identifies a single shared raw-material supplier tying all four recalls together, and FDA has not announced a formal investigation linking them. But the clustering itself is the operationally relevant fact for quality professionals at any compounding pharmacy handling this drug category: four independent firms finding contamination problems in the same product type over the same short window is a pattern worth treating as a signal, whatever its eventual root cause turns out to be — particularly for firms sourcing dietary-supplement-grade glutathione active ingredient rather than material intended and tested for injectable use.

What FDA has not yet said

As of this recall's announcement, FDA had not publicly assigned it a recall classification (Class I, II or III), and the agency's notice does not state whether the recall followed routine company testing, a patient complaint, or an FDA inspection. A comparable 2026 glutathione recall from Victory Medical Center Pharmacy was classified Class I, FDA's most serious designation, reserved for situations where there is a reasonable probability a product will cause serious adverse health consequences or death — but that classification applies to a different company's recall, not this one, and should not be assumed to carry over.

Frequently asked questions

What did Greenwich Rx recall?

Ten lots of compounded Glutathione Injection, 200 mg/mL, packaged in 10 mL multidose vials and labelled for subcutaneous injection, recalled voluntarily and nationwide on 1 October 2026 due to potentially elevated endotoxin levels found on testing.

What is the health risk?

Endotoxin is a bacterial toxin that can be present and dangerous even when no live organism remains. FDA's recall notice warns that an endotoxin-contaminated injectable can cause fever, chills, hypotension, systemic inflammatory response, and in severe cases anaphylactic shock or death if administered, particularly intravenously.

Were there adverse events?

Greenwich Rx's recall notice references two emergency department visits involving patients who received the product intravenously, a route the labelling does not support; the product is labelled for subcutaneous injection only. The company has characterized the IV administration as off-label use rather than a defect specific to that route, independent of the endotoxin finding that triggered the recall itself.

Is this an isolated incident?

No. Greenwich Rx is the fourth Texas compounding pharmacy to recall injectable glutathione since August 2026, following Victory Medical Center Pharmacy in Austin, Optimal Balance Pharmacy in Houston, and Centric Compounding in Houston — all citing contamination or quality issues in the same drug category within roughly two months of each other.